A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease

NCT06748079 | Completed Phase 1

• 1 other identifier: TQC3721-D8-I-01
• Study Type: interventional
• Target: 113
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, double-blind, placebo-controlled, dose escalation, multicenter study design. The purpose is to evaluate the safety, tolerability, pharmacokinetics, and pharmacokinetic characteristics of TQC3721 inhalation powder in Chronic Obstructive Pulmonary Disease(COPD) patients with single/multiple dose escalation.

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Outcome Measures

Primary Outcomes (3)

• Adverse events (AE)

  Incidence of adverse events (AE)

  21 days

• Serious Adverse Events (SAE)

  Incidence of Serious Adverse Events (SAE)

  21 days

• Treatment-emergent adverse events (TEAEs)

  Incidence of treatment-emergent adverse events (TEAEs)

  19 days

Secondary Outcomes (4)

• Plasma drug peak concentration

  9 days

• COPD Assessment Tes (CAT) scores

  From day 1 to day 11 or end of treatment, whichever came first

• PD indices: Pulmonary function test parameters

  From D-1 to End of Treatment(EOT).

• Serum and sputum inflammatory cells

  From D-1 to D11 or End of EOT)

Study Arms (3)

TQC3721 inhalation powder

EXPERIMENTAL

TQC3721 inhalation powder is administered as a single dose or continuously for 7 days.

Drug: TQC3721 inhalation powder

Placebo for TQC3721 inhalation powder

PLACEBO COMPARATOR

Placebo for TQC3721 inhalation powder inhalation is administered as a single dose or continuously for 7 days.

Drug: Placebo for TQC3721 inhalation powder

TQC3721 Inhaler Powder + Glimetrexate Inhaler Powder / Control Group

EXPERIMENTAL

TQC3721 inhalation powder combined with glyberlam inhalation powder or a control group for 14 consecutive days of inhalation administration.

Drug: TQC3721 inhalation powder combined with glyberlam inhalation powder or a control group

Interventions

TQC3721 inhalation powder DRUG

TQC3721 is a target inhibitor.

TQC3721 inhalation powder

Placebo for TQC3721 inhalation powder DRUG

Placebo without drug substance.

Placebo for TQC3721 inhalation powder

TQC3721 inhalation powder combined with glyberlam inhalation powder or a control group DRUG

TQC3721 is a target inhibitor

TQC3721 Inhaler Powder + Glimetrexate Inhaler Powder / Control Group

Eligibility Criteria

• Age: 40 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age: 40-75 years old, male or female;
• During screening, according to the Global Oceanographic Library for Discovery (GOLD)guidelines (2024), patients diagnosed with stable moderate to severe COPD should have Force Expiratory Volume in 1 second (FEV1)/ forced vital capacity (FVC)\<0.7 after inhaling bronchodilators; 40% ≤ FEV1 accounts for ≤ 80% of the expected value;
• When screening, after inhaling salbutamol aerosol for 4 times, there is a certain reversibility in the airway: the absolute value of FEV1 improves by more than 100ml;
• Applicable to Part 1: Being able to adjust the current COPD treatment or for COPD patients with initial treatment, prescribed bronchodilators, including Long-acting Muscarinic Antagonists (LAMA) and/or Long-acting β2-agonist (LABA) inhaled drugs, can be discontinued during the screening period after signing the informed consent form; 4.2 Applicable to Part 2: Being able to adjust the current COPD treatment or for COPD patients with initial treatment,LAMA inhaled drugs can be used during the lead-in period after signing the informed consent form;
• The subject is able to discontinue Short acting Beta agonists (SABA) for at least 6 hours and Short acting Anticholinergic Agents (SAMA) for at least 8 hours; 6.Smoking history ≥ 10 pack years (pack years: number of packs per day multiplied by smoking years); 7.There is no evidence to suggest active respiratory and/or cardiovascular diseases other than COPD in clinical practice (such as uncontrolled hypertension); 8.No other related lung diseases or history of thoracic surgery; 9.The subjects were able to undergo reproducible FEV1 lung function testing according to the ATS/ERS 2005 standard during screening; 10. Body mass index (BMI) is between 18-30kg/m2; 11.Participants must agree to use contraceptive methods (such as birth control pills, condoms, or intrauterine devices) with sexual partners of childbearing age during the clinical trial period (screening period to 30 days after the last dose); 12) The subject is able to use a dry powder inhaler correctly for inhalation. 13) I have fully understood this study and voluntarily participated. I have signed the 'Informed Consent Form'.

You may not qualify if:

• History or current clinical instability of heart, respiratory, endocrine, metabolic, renal, liver, gastrointestinal, skin, infection, blood system, nervous system, or neurological/psychiatric disorders/abnormalities; 2. The result of the human immunodeficiency virus (HIV) antibody test is positive; The result of hepatitis B surface antigen (HBsAg) test is positive (if HBsAg is positive, Hepatitis B virus deoxyribonucleic acid (HBV-DNA) should be checked if necessary, and if HBV-DNA\<Lower Limit of Quantification (LLOQ), it does not need to be excluded); Hepatitis C virus (HCV) antibody positive and confirmed presence of HCV ribonucleic acid (RNA); Positive for Treponema pallidum antibody (TPPA); 3. Have a history of illegal drug abuse in the past; 4. Have participated in other clinical trials and received the investigational drug within 3 months prior to participating in this trial, or within 5 half lives of the investigational drug, whichever is shorter; 5. Those who have lost blood or donated more than 400 mL of blood within 2 months before the experiment; 6. Have any clear and severe history of drug or food allergies, especially those who are allergic to ingredients similar to the investigational drug; 7. Drinking history (drinking 14 units of alcohol per week: 1 unit=285 ml of beer; or 25 ml of spirits; or 1 glass of wine); 8. History of malignant tumors in any organ system within the past 5 years, regardless of whether treatment has been received or not, except for local basal cell carcinoma of the skin; 9. Lower respiratory tract infection occurred within 6 weeks before screening or randomization. Upper respiratory tract infections requiring antibiotics within 6 weeks prior to screening or randomization; 10. Have a history of active tuberculosis, bronchiectasis, asthma or other non-specific lung diseases.
• \. QTcF (corrected QT interval, Fridericia formula QT \[msec\]/RR \[s\]) interval, male\>450ms, female\>470ms, or history of long QT syndrome before screening or randomization; 12. Subjects with a history of drug use in the past 2 years; 13. Subjects who are unable to comply with past medication and concomitant medication restrictions; 14. If there is a history of acute exacerbation of COPD within 3 months before screening or randomization, hospitalization or additional COPD maintenance treatment is required. Over the past three years, the average number of frequent exacerbations of COPD with moderate to severe severity has been ≥ 2 per year, or resulting in hospitalization for ≥ 2 acute exacerbations per year; 15. Oral non selective beta blockers; 16. Previously treated with TQC3721 suspension. 17. Any situation that researchers believe may pose safety risks to subjects in the trial or may interfere with the conduct of this study, or where researchers believe that subjects may not be able to complete this study or may not be able to comply with the requirements of this study (due to management or other reasons).

Sponsors & Collaborators

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.: lead

Study Sites (1)

West China Hospital of Sichuan University

Chengdu, Sichuan, 610000, China

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 18, 2024
• First Posted: December 24, 2024
• Study Start: December 3, 2024
• Primary Completion: August 7, 2026
• Study Completion: August 7, 2026
• Last Updated: August 11, 2026

Record last verified: 2026-08

Locations

CN (1)